Brian Cheng
Stock Analyst at JP Morgan
(2.04)
# 2,866
Out of 5,178 analysts
77
Total ratings
42%
Success rate
-8.09%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XNCR Xencor | Downgrades: Neutral | $18 → $13 | $12.40 | +4.84% | 6 | Mar 24, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $95 → $106 | $104.31 | +1.62% | 7 | Mar 19, 2026 | |
| TARA Protara Therapeutics | Initiates: Overweight | $27 | $5.31 | +408.47% | 1 | Mar 4, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Overweight | $29 | $11.07 | +161.97% | 1 | Mar 2, 2026 | |
| TGTX TG Therapeutics | Maintains: Overweight | $49 → $46 | $31.82 | +44.56% | 1 | Feb 2, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $92 → $122 | $94.29 | +29.39% | 2 | Feb 2, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $70 → $125 | $78.93 | +58.37% | 1 | Dec 10, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.19 | - | 1 | Nov 20, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Underweight | $12 → $5 | $13.26 | -62.29% | 5 | Nov 7, 2025 | |
| ZYME Zymeworks | Maintains: Overweight | $20 → $23 | $24.23 | -5.08% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.33 | - | 5 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.31 | - | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $2.92 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $33 | $24.76 | +33.28% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $47 | $65.81 | -28.58% | 2 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $27.36 | -26.90% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $47.09 | +48.65% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.10 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $20.30 | +8.37% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $22.38 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.32 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $7.87 | +319.31% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.39 | +331.65% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.16 | +8,755.15% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.97 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $320 → $96 | $6.81 | +1,309.69% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.88 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.38 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $7.06 | +1,103.97% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $9.40 | +123.40% | 1 | Aug 3, 2021 |
Xencor
Mar 24, 2026
Downgrades: Neutral
Price Target: $18 → $13
Current: $12.40
Upside: +4.84%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Overweight
Price Target: $95 → $106
Current: $104.31
Upside: +1.62%
Protara Therapeutics
Mar 4, 2026
Initiates: Overweight
Price Target: $27
Current: $5.31
Upside: +408.47%
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $29
Current: $11.07
Upside: +161.97%
TG Therapeutics
Feb 2, 2026
Maintains: Overweight
Price Target: $49 → $46
Current: $31.82
Upside: +44.56%
Revolution Medicines
Feb 2, 2026
Maintains: Overweight
Price Target: $92 → $122
Current: $94.29
Upside: +29.39%
Kymera Therapeutics
Dec 10, 2025
Maintains: Overweight
Price Target: $70 → $125
Current: $78.93
Upside: +58.37%
OPKO Health
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.19
Upside: -
Intellia Therapeutics
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $13.26
Upside: -62.29%
Zymeworks
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $24.23
Upside: -5.08%
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.33
Upside: -
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.31
Upside: -
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $2.92
Upside: -
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $24.76
Upside: +33.28%
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $65.81
Upside: -28.58%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $27.36
Upside: -26.90%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $47.09
Upside: +48.65%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $3.10
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $20.30
Upside: +8.37%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $22.38
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.32
Upside: -
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $7.87
Upside: +319.31%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.39
Upside: +331.65%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.16
Upside: +8,755.15%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.97
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $320 → $96
Current: $6.81
Upside: +1,309.69%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $0.88
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.38
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $7.06
Upside: +1,103.97%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $9.40
Upside: +123.40%